| 4.76 -0.1 (-2.06%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.43 | 1-year : | 10.32 |
| Resists | First : | 7.22 | Second : | 8.84 |
| Pivot price | 5.39  |
|||
| Supports | First : | 4.59 | Second : | 3.82 |
| MAs | MA(5) : | 4.9 |
MA(20) : | 6.1 |
| MA(100) : | 6.68 |
MA(250) : | 6.17 |
|
| MACD | MACD : | -0.8  |
Signal : | -0.8 |
| %K %D | K(14,3) : | 7.3 |
D(3) : | 8.4 |
| RSI | RSI(14): 30.3 |
|||
| 52-week | High : | 11.44 | Low : | 3.34 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ELTX ] has closed above bottom band by 28.7%. Bollinger Bands are 40.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.96 - 4.99 | 4.99 - 5.02 |
| Low: | 4.68 - 4.71 | 4.71 - 4.75 |
| Close: | 4.7 - 4.76 | 4.76 - 4.81 |
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Wed, 16 Apr 2025
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires - GlobeNewswire
Wed, 16 Apr 2025
Key Executive Appointment: Elicio Therapeutics Names New Chief Strategy and Financial Officer - Stock Titan
Fri, 04 Apr 2025
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Mon, 31 Mar 2025
Elicio's Latest Financial Results Reveal Key Clinical Milestones and 28.9-Month Survival Data - Stock Titan
Mon, 31 Mar 2025
Elicio Therapeutics Advances Cancer Immunotherapy Pipeline - TipRanks
Mon, 31 Mar 2025
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 8.58e+006 (%) |
| Held by Institutions | 43.6 (%) |
| Shares Short | 140 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.467e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -101.7 % |
| Return on Equity (ttm) | -170 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.56 |
| Qtrly Earnings Growth | -4.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 170040 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|